Skip to main content
. 2022 Jan 20;43(34):3198–3208. doi: 10.1093/eurheartj/ehab841

Graphical Abstract.

Graphical Abstract

The future evolution of lipid-lowering therapies. The quest for new lipid-lowering therapies enabling less frequent administration is continuing. Outcome trials to show cardiovascular event reduction will determine their clinical application. ASO, antisense oligonucleotide; CV, cardiovascular; IPE, icosapent ethyl; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); MoAb, monoclonal antibodies; siRNA, small-interfering RNA.